US 10968278
Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 10968278 (Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/519